Welcome to our dedicated page for ZIMMER BIOMET HOLDINGS SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZIMMER BIOMET HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZIMMER BIOMET HOLDINGS's regulatory disclosures and financial reporting.
ZIMMER BIOMET HOLDINGS, INC. executive vice president and CFO Suketu Upadhyay reported an acquisition of 10,217 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock at no purchase price.
The RSUs were originally granted as performance-based awards on March 6, 2023, with results tied to a performance period covering 2023 to 2025. Based on actual performance determined on February 19, 2026, 10,217 RSUs were earned and are scheduled to vest on March 6, 2026, if vesting conditions are satisfied.
ZIMMER BIOMET HOLDINGS, INC. reported that executive Paul A. Stellato, its VP, Controller and Chief Accounting Officer, acquired 1,363 restricted stock units as part of a performance-based equity award. These RSUs were earned based on performance for the 2023–2025 period and are scheduled to vest on March 6, 2026.
Zimmer Biomet Holdings senior vice president and chief legal officer Chad F. Phipps reported an equity award tied to past performance. He acquired 4,692 restricted stock units as of February 19, 2026, at a stated price of $0.00 per unit. These RSUs were earned under a performance-based grant covering the 2023–2025 period and are scheduled to vest on March 6, 2026. Each RSU represents the right to receive one share of Zimmer Biomet common stock.
Zimmer Biomet Holdings reported that Group President, Asia Pacific, Yi Sang acquired 7,050 restricted stock units (RSUs) at a price of $0.00 per unit. These RSUs were earned from performance-based awards granted in March and September 2023 for the 2023–2025 performance period.
Based on actual performance determined on February 19, 2026, Yi Sang earned 5,298 RSUs from the March 2023 grant and 1,752 RSUs from the September 2023 grant. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and the 7,050 RSUs will vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. Chairman, President and CEO Ivan Tornos reported an acquisition of 24,436 restricted stock units (RSUs) tied to prior performance-based awards. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock at no purchase price.
The RSUs relate to performance-based grants awarded in March and September 2023 for a 2023–2025 performance period. Based on actual performance determined on February 19, 2026, he earned 12,184 RSUs from the March grant and 12,252 RSUs from the September grant, which together will vest on March 6, 2026 if conditions are satisfied.
Zimmer Biomet Holdings, Inc. files its annual report describing a global orthopedic and musculoskeletal business built around knees, hips, S.E.T. (sports medicine, extremities, trauma, CMFT) and a growing digital and robotic ZBEdge platform. The company sells mainly through consignment, which represented about 85% of 2025 net sales, with no single customer over 2%.
Operations are organized into Americas, EMEA and Asia Pacific, with the U.S. dominating Americas and Japan leading Asia Pacific. As of February 10, 2026, there were 195,652,004 common shares outstanding, and non‑affiliate share value was about $18.0 billion as of June 30, 2025.
Zimmer Biomet highlights extensive R&D with roughly 2,000 employees, heavy regulation from FDA, EU MDR and other regimes, and growing scrutiny on data privacy, cybersecurity and AI. The report details risks around competition, pricing pressure, restructuring, product portfolio rationalization, supply chain, ERP implementation issues, cyber attacks, high leverage of about $7.5 billion of debt, tax changes and global macro uncertainty.
Harris Associates has disclosed a sizable stake in Zimmer Biomet Holdings, Inc. common stock. Through Harris Associates L.P. and Harris Associates, Inc., the firm reports beneficial ownership of 12,264,703 shares, representing 6.2% of Zimmer Biomet’s common stock.
Harris reports sole voting power over 11,892,571 shares and sole dispositive power over 12,264,703 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Zimmer Biomet.
Yi Sang reported open-market sale transactions in a Form 4 filing for ZBH. The filing lists transactions totaling 1,000 shares at a weighted average price of $96.49 per share. Following the reported transactions, holdings were 17,670 shares.
A shareholder of ZBH has filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 1,000 shares of common stock, with an aggregate market value of 96,490.00, to be sold through Fidelity Brokerage Services LLC on the NYSE around February 12, 2026.
The shares were originally acquired from the issuer on March 6, 2024 through restricted stock vesting as part of compensation, rather than a cash purchase. By signing the notice, the seller represents that they are not aware of any material adverse, non-public information about the issuer’s current or prospective operations.
Zimmer Biomet reported solid 2025 growth with mixed earnings trends and new capital return plans. Fourth quarter net sales were $2.244 billion, up 10.9% reported and 5.4% on an organic constant currency basis. Full-year net sales reached $8.232 billion, an increase of 7.2% reported and 3.9% on an organic constant currency basis.
GAAP diluted EPS fell to $0.70 in the quarter, down 41.7%, and to $3.55 for the year, down 19.9%, largely reflecting higher costs and charges. Adjusted diluted EPS was $2.42 for the quarter, up 4.8%, and $8.20 for the year, up 2.5%. The company generated $1.697 billion in operating cash flow and $1.172 billion of free cash flow in 2025.
The Board authorized a new $1.5 billion stock repurchase program with no expiration date, after completing $250 million of buybacks in the fourth quarter. For 2026, Zimmer Biomet guides to reported revenue growth of 2.5%–4.5%, organic constant currency growth of 1.0%–3.0%, and adjusted diluted EPS of $8.30–$8.45, as it shifts toward a more direct and specialized U.S. sales model.